CAERS, J., Duray, E., Dumoulin, M., & D’Huyvetter, M. (2023). ANTI-CD38 SINGLE-DOMAIN ANTIBODIES IN DISEASE MONITORING AND TREATMENT. |
  | Köse, M. C., Lejeune, M., Gou, M.-J., Duray, E., Cobraiville, G., Gothot, A., Beguin, Y., Fillet, M., & Caers, J. (15 November 2022). Integrative Analysis of Proteomics and Transcriptomics Reveals the Etrb As Novel Single Target and New Combinatorial Targets for Multiple Myeloma [Paper presentation]. ASH 2022 Symposium, New orleans, United States. |
 | Caers, J., Duray, E., Vrancken, L., Marcion, G., Bocuzzi, V., De Veirman, K., Krasniqi, A., Lejeune, M., Withofs, N., Devoogdt, N., Dumoulin, M., Karlström, A. E., & D'Huyvetter, M. (2022). Radiotheranostic Agents in Hematological Malignancies. Frontiers in Immunology, 13, 911080. doi:10.3389/fimmu.2022.911080  Peer Reviewed verified by ORBi |
 | Vrancken, L., Lejeune, M., PIROTTE, M., Duray, E., Köse, M. C., BEGUIN, Y., & CAERS, J. (2021). Le myélome multiple : un tour d’horizon des nouveautés dans sa biologie et son traitement. Revue Médicale de Liège, 76, 482-488. Peer reviewed |
 | Lejeune, M., Duray, E., Peipp, M., Clémenceau, B., Baron, F., Beguin, Y., & Caers, J. (2021). Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma. Cancers, 13 (12), 3072. doi:10.3390/cancers13123072 Peer Reviewed verified by ORBi |
 | Duray, E., Lejeune, M., Baron, F., Beguin, Y., Devoogdt, N., Krasniqi, A., Lauwers, Y., Zhao, Y. J., D'Huyvetter, M., Dumoulin, M., & Caers, J. (2021). A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma. Journal of hematology & oncology, 14 (1), 183. doi:10.1186/s13045-021-01171-6 Peer reviewed |
 | Lejeune, M., Köse, M. C., Duray, E., Einsele, H., Beguin, Y., & Caers, J. (07 May 2020). Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies. Frontiers in Immunology, 11 (762), 1-20. doi:10.3389/fimmu.2020.00762 Peer Reviewed verified by ORBi |
 | Lejeune, M., Köse, M. C., Duray, E., Beguin, Y., & CAERS, J. (2020). Les anticorps bispécifiques ciblant les lymphocytes T dans le myélome multiple. OncoHemato : Revue Multidisciplinaire d'Oncologie et Hématologie, 14 (6), 30-34. Peer reviewed |
 | Bolomsky, A., Muller, J., Stangelberger, K., Lejeune, M., Duray, E., Breid, H., Vrancken, L., Pfeiffer, C., Hübl, W., Willheim, M., Weetall, M., Branstrom, A., Zojer, N., Caers, J., & Ludwig, H. (2020). The anti-mitotic agents PTC-028 and PTC596 display potent activity in pre-clinical models of multiple myeloma but challenge the role of BMI-1 as an essential tumour gene. British Journal of Haematology, 190, 877-890. doi:10.1111/bjh.16595 Peer Reviewed verified by ORBi |
 | Muller, J., Duray, E., Lejeune, M., DUBOIS, S., Plougonven, E., Léonard, A., Storti, P., Giuliani, N., Cohen-Solal, M., Hempel, U., Thijssen, V., BEGUIN, Y., Heusschen, R., & CAERS, J. (2019). Loss of stromal galectin-1 enhances multiple myeloma development: Emphasis on a role in osteoclasts. Cancers, 11 (2), 261. doi:10.3390/cancers11020261 Peer Reviewed verified by ORBi |
 | Cawez, F., Duray, E., Hu, Y., Vandenameele, J., Romao, E., Vinckle, C., Dumoulin, M., Galleni, M., Muyldermans, S., & Vandevenne, M. (25 May 2018). Combinatorial Design of a Nanobody that Specifically Targets Structured RNAs. Journal of Molecular Biology, 430 (11), 1652-1670. doi:10.1016/j.jmb.2018.03.032 Peer Reviewed verified by ORBi |
  | Heusschen, R., Muller, J., Duray, E., WITHOFS, N., Bolomsky, A., Baron, F., Beguin, Y., Menu, E., Ludwig, H., & Caers, J. (2018). Molecular mechanisms, current management and next generation therapy in myeloma bone disease. Leukemia and Lymphoma, 59, 14-28. doi:10.1080/10428194.2017.1323272 Peer Reviewed verified by ORBi |
 | Muller, J., Bolomsky, A., Dubois, S., Duray, E., Stangelberger, K., Plougonven, E., Lejeune, M., Léonard, A., Marty, C., Hempel, U., Baron, F., BEGUIN, Y., Cohen-Solal, M., Ludwig, H., Heusschen, R., & CAERS, J. (2018). Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity on multiple myeloma bone disease. Haematologica, 103, 1359-1368. doi:10.3324/haematol.2017.185397 Peer Reviewed verified by ORBi |